Oslo, 22 January 2025 Reference is made to the stock exchange announcement made by Belships ASA (“Belships” or the “Company“) on 21 January 2025, regarding the approval of the offer document (the “Offer Document“) by Blue Northern BLK Ltd. (“Blue Northern” or the “Offeror“) for the recommended voluntary cash tender offer (the “Offer“) to acquire all issued and outstanding shares of Belships (the “Shares“) against a cash consideration of NOK 20.50 (the “Offer Price“) per Share, and commencement of the offer period today, 22 January 2025. Reference is further made to the stock exchange announcement made by the Company on 19 December 2024, pursuant to which it was disclosed that the members of the Company’s board of directors (the “Board“)...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues. The tests use highly sensitive, gold-standard PCR technology, providing results in 20 minutes to allow healthcare providers to confidently diagnose and determine appropriate treatment in the same visit.Basel, 22 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas® liat sexually transmitted infection (STI) multiplex...

Nokia Corporation Stock Exchange Release22 January 2025 at 08:00 EET Patrik Hammarén appointed as President of Nokia TechnologiesPatrik Hammarén appointed as President of Nokia Technologies and member of the Nokia Group Leadership TeamEspoo, Finland – Nokia today announced the appointment of Patrik Hammarén as President of Nokia Technologies and member of the Nokia Group Leadership Team, effective 22 January 2025. Nokia Technologies is responsible for managing and monetizing Nokia’s intellectual property, including the company’s industry leading patent portfolio. The business group licenses Nokia’s innovation and contributions to global technology standards to other companies. Hammarén joined Nokia in 2007 and has been acting President of Nokia Technologies since October 2024. Prior to this role, Patrik held several senior positions...

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myelomaApproval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMM Represents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMMParis, January 22, 2025. Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed...

The savings, which would come at greater or equal effectiveness, could generate up to $1 trillion in additional lending capacity DAVOS, Switzerland, Jan. 22, 2025 (GLOBE NEWSWIRE) — Between $25 billion and $50 billion in potential efficiency gains can be realized through targeted enhancements in banks’ Risk and Compliance functions alone without compromising effectiveness, according to a report released by Nasdaq and Boston Consulting Group (BCG). The report, titled “The New Growth Imperative: Cutting through Complexity in the Financial System” reviews the interconnected challenge of complexity and complicatedness and finds that while external complexity continues to increase, excess layers of internal complicatedness have accumulated. “Financial institutions are particularly exposed to the exponential growth in complexity...

WHITE SULPHUR SPRINGS, Mont., Jan. 21, 2025 (GLOBE NEWSWIRE) — Sandfire Resources America Inc. (“Sandfire America” or the “Company“) announces that Gemma Tually has been appointed to the Sandfire America Board of Directors effective immediately. This occurs in conjunction with Victoria Twiss stepping down from her seat on the Board. Ms. Tually is the Chief Legal & Compliance Officer for Sandfire Resources Ltd. (Australia); 86.9% owner of Sandfire America’s outstanding shares. Ms. Tually is a qualified solicitor with more than 20 years of legal experience working across areas including mining, dispute resolution, international trade and transport, finance, and corporate law. The Company welcomes Ms. Tually to the SFR Board and extends its sincere thanks to Ms. Twiss for her contributions to the Board...

GUANGZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company, announced the launch of its Exhibition (Experience) Center in Shenzhen’s Luohu Sports and Leisure Park. It is the world’s first EH216-S takeoff and landing site featuring a fully automated vertical lift vertiport. It also marks a new smart infrastructure in Shenzhen dedicated to the commercial operations of the EH216-S pilotless passenger-carrying aerial vehicle, establishing a groundbreaking model for electric vertical takeoff and landing (“eVTOL”) aircraft operations in urban areas.(Image: The Luohu UAM Exhibition (Experience) Center) The Luohu UAM Center, designed by EHang, boasts an automated three-dimensional vertical lift vertiport....

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) — Tactical Resources Corp. (TSXV: RARE) (OTC: USREF) (“Tactical Resources” or the “Company”) is pleased to announce that the Company has completed a non-brokered private placement of unsecured convertible debentures (the “Debentures”) in the principal amount of $500,000 with certain third-party lenders (the “Private Placement”). The Debentures have a maturity date of January 21, 2027 (the “Maturity Date”) and may be converted into units of the Company (the “Units”) at any time from the date of issuance until the Maturity Date, at a conversion price of $0.20 per Unit (the “Conversion...

Announces intent to spin out and form a growth-oriented joint venture for LanzaX, the Company’s differentiated synthetic biology platform, with Tharsis Capital joining as new LanzaX strategic partner to accelerate financing for the synbio development pipeline Appoints new Interim Chief Financial Officer of LanzaTech to streamline biorefining platform growth priorities and heighten focus on cost reductions CHICAGO, Jan. 21, 2025 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or “the Company”), the carbon recycling company transforming waste carbon into sustainable fuels, chemicals, materials, and protein, today announced its intent to form LanzaX, a business unit dedicated to its wholly-owned synthetic biology platform. LanzaTech intends to spin out LanzaX from its core biorefining business as a joint venture...

NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced today announced it has entered into agreements with certain holders of its existing warrants exercisable for 4,971,110 shares of its common stock, in the aggregate, to exercise outstanding warrants at a reduced exercise price of $0.751 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $3.7 million, before deducting financial advisory fees. The exercisability of the new warrants and any resulting issuance of the shares underlying the new warrants are subject to...